ArticlePloS one2026
The identification of metabolites from gut microbiota in HPV infection via network pharmacology.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) infection continues to pose a significant global health challenge. Although gut microbial metabolites have been associated with HPV infection, the mechanisms underlying this relationship remain inadequately understood. A network pharmacology approach was utilized to comprehensively explore the connections between gut microbial metabolites and HPV infection. Using gutMGene, GeneCards, OMIM and other databases, 43 key targets were identified as common elements between gut microbial metabolites and HPV infection. Protein-protein interaction network analysis further screened 10 core targets, including IL6, AKT1, IL1B, CASP3, NFKB1, EGFR, PPARG, JUN, PTGS2, and TLR4. Gene ontology (GO) enrichment analysis of these 43 key targets indicated their involvement in lipopolysaccharide response, oxidative stress, and inflammatory signaling. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of the 10 core targets highlighted the TNF, Toll-like receptor, C-type lectin receptor, and IL-17 signaling pathways as the main enriched pathways. A comprehensive microbiota-metabolite-target-pathway network was constructed, illustrating that these core targets interact with 13 gut microbial metabolites, 97 gut microbes, and 10 key pathways. Among the 13 metabolites screened, succinate and short-chain fatty acids (acetate, butyrate, propionate) exhibited favorable drug-likeness and toxicological profiles, with succinate being the most notable. Molecular docking analysis indicated that succinate binds to IL1B with a binding energy of -5.66 kcal/mol, suggesting a potential interaction with this core inflammatory target. These results suggest that key gut microbial metabolites, particularly succinate, may influence HPV infection through immune-related pathways and potential interactions with IL1B. This study provides a new direction for understanding the relationship between microbial metabolites and HPV infection and offers a foundation for future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.